medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (4)

Evolution of methods for the detection of hemophilia inhibitors

Tejeda GM, Castillo GD

Language: Spanish
References: 15
Page: 1-7
PDF size: 250.69 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479-86.

  2. Margaglione M, Intrieri M. Genetic Risk Factors and Inhibitor Development in Hemophilia: What Is Known and Searching for the Unknown.SeminThrombHemost. 2018;44(6):509-16.

  3. Castillo-González D, Martínez-Triana R, Lavaut-Sánchez K, Verdura-Trujillo A, Callejas-Turiño Y, Reyes-Caballero O. Hemofilia y enfermedad de von Willebrand. Guías de actuación. La Habana: Ciencias Médicas; 2018.

  4. Miller CH. Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review. Haemophilia. 2018;24(2):186-97.

  5. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34(2):612.

  6. Grosso S, Blanco A. Inhibidores específicos neutralizantes. En: Blanco A, Kordich L (eds.) Fundamentos para el manejo práctico en el laboratorio de hemostasia. 2.a ed. Buenos Aires: Grupo CAHT; 2013. P. 525-83.

  7. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995 Feb;73(2):247-51.

  8. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII: C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost.1998;79(4):872-5.

  9. de Lima Montalvão SA, Tucunduva AC, de Almeida Sambo AL, De Paula EV, de Souza Medina S, Ozelo MC. Heat treatment of samples improve the performance of the Nijmegen-Bethesda assay in hemophilia A patients undergoing immune tolerance induction. Thromb Res. 2015;136(6):1280-4. DOI: http://10.1016/j.thromres.2015.08.014

  10. Arias M. Actualización en diagnóstico inhibidor de factor VIII. Rev Hematología. 2016; 20:174-9 Disponible en: http://www.sah.org.ar/revista/numeros/24-vol-20-congre-2016.pdf

  11. Favaloro EJ, Verbruggen B, Miller CH. Laboratory testing for factor inhibitors. Haemophilia. 2014;20 (Suppl 4):94-8. DOI: http://10.1111/hae.12408

  12. Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, et al. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. J Thromb Haemost. 2015;13(1):47-53.

  13. Miller CH, Boylan B, Shapiro AD, Lentz SR, Wicklund BM. Limit of Detection and Threshold for Positivity of the Centers for Disease Control and Prevention Assay for Factor VIII Inhibitors. Thromb Haemost. 2017;15(10):19716.

  14. Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, et al. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost. 2013;11(7):1300-9. DOI: http://10.1111/jth.12259

  15. Raut S, Heath A. South Mimms Inhibitor Assay (SMIA): An affordable and improved method form measurement of FVIII inhibitors. Presented at WFH congress 2016. [acceso 15/01/2020]. Disponible en: https://www.postersessiononline.eu/173580348_eu/congresos/WFH2016/aula/-PP-W_78_WFH2016.pdF




2020     |     www.medigraphic.com